Saturday, March 15, 2025 | 02:20 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Rising rupee another risk for Indian pharma

Companies would also have levers like cost cutting to mitigate some of the pressure

Note: Figures for 9M FY 2017;  (sales contribution of US business of DRL was 50.7% in  FY16)
Premium

Note: Figures for 9M FY 2017; (sales contribution of US business of DRL was 50.7% in FY16)

Aneesh Phadnis Mumbai
Pricing pressure and regulatory issues are not the only thing worrying executives of Indian pharmaceuticals companies.

Weakening of the dollar versus the rupee in the first four months of this calendar year is adding to the concerns; it might impact their earnings by five or six per cent. An appreciation in the rupee versus the dollar means every one of the latter yields less of the former, whereas a lot of the costs are denominated in rupees. Dr Reddy’s Laboratories (DRL), Lupin and Sun Pharmaceutical earn close to half their revenue from the US market. DRL has the highest

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in